A Phase I clinical trial of a novel T cell-inducing HIV vaccine candidate has launched in Africa to evaluate immune responses to highly networked HIV T-cell epitopes. The trial is a collaboration between The Mutala Trust, ReiThera Srl (ReiThera), the Ragon Institute of Mass General Brigham, MIT,… Read More
A heavily pretreated patient with aggressive Grade 3 non-germinal centre diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase I clinical trial of Lantern Pharma’s LP-284. Lantern uses an AI approach to determine mechanisms of action of any cancer focused molecule, identify… Read More
Monte Rosa Therapeutics has dosed the first subjects in a Phase I study evaluating MRT-8102, a NEK7-directed molecular glue degrader (MGD) being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1β, and IL-6. Initial results from the Phase I study are expected in… Read More
Biotech Cellarity has dosed its first patient in a Phase I clinical trial of CLY-124, a first-in-class Globin-Switching oral medicine designed to treat sickle cell disease (SCD). “Initiation of our first-in-human clinical study for CLY-124 represents the delivery of our first clinical asset from our platform with… Read More
The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer. This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More
Breye Therapeutics is a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases. The company has now completed its Phase Ib clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated oedema. Read More
The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours. The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik. Read More
Redx Pharma has shared additional results from an RXC008 Phase I clinical trial at Digestive Disease Week 2025, San Diego, CA. RXC008 is a highly potent pan-Rho-associated coiled-coil kinase (pan-ROCK) inhibitor that was designed to be restricted to the gastrointestinal (GI) tract. The Phase I… Read More
Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours. The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours. The study’s primary objectives… Read More
Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development. The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More
MetaVia has announced positive results from the four-week multiple ascending dose (MAD) Part 2 of its Phase I clinical trial of DA-1726 for the treatment of obesity. DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor… Read More
RiboX Therapeutics has dosed the first patient in its first-in-human (FIH) Phase I/IIa clinical trial (SPRINX-1) evaluating the safety and efficacy of RXRG001 in patients with radiation-induced-xerostomia (RIX) and hyposalivation. RXRG001 is the first circular RNA therapy to receive FDA IND clearance. Xerostomia and hyposalivation… Read More
Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity. HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More
Satellos Bioscience has shared positive initial Phase I data for its small molecule drug candidate SAT-3247 at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas. SAT-3247 is designed to address progressive muscle loss in Duchenne muscular dystrophy (DMD) patients by aiming to… Read More
Vivani Medical has announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial. The company hopes to address one of healthcare’s most pressing challenges: medication adherence in metabolic diseases including chronic weight management and type 2 diabetes. Vivani also announced… Read More
A clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore. Lassa fever is a viral haemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of those who… Read More
